Is Treatment-resistant Schizophrenia a Neuroimmune Condition? Meta-analytic Evidence from Magnetic Resonance Spectroscopy
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Siskind D, Siskind V, Kisely S
. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can J Psychiatry. 2017; 62(11):772-777.
PMC: 5697625.
DOI: 10.1177/0706743717718167.
View
2.
de Bartolomeis A, Ciccarelli M, Vellucci L, Fornaro M, Iasevoli F, Barone A
. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opin Pharmacother. 2022; 23(18):2035-2052.
DOI: 10.1080/14656566.2022.2145884.
View
3.
Potkin S, Kane J, Correll C, Lindenmayer J, Agid O, Marder S
. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020; 6(1):1.
PMC: 6946650.
DOI: 10.1038/s41537-019-0090-z.
View
4.
Lesh T, Maddock R, Howell A, Wang H, Tanase C, Ragland J
. Extracellular free water and glutathione in first-episode psychosis-a multimodal investigation of an inflammatory model for psychosis. Mol Psychiatry. 2019; 26(3):761-771.
PMC: 6881530.
DOI: 10.1038/s41380-019-0428-y.
View
5.
Hu X, Zhou H, Zhang D, Yang S, Qian L, Wu H
. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J Neuroimmune Pharmacol. 2011; 7(1):187-201.
PMC: 3633602.
DOI: 10.1007/s11481-011-9309-0.
View